Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
…, EB Ramiterre, BHM Reyes, PP Tan, JY Choe… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
[HTML][HTML] A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients …
…, LC Roberto, E Amante, AE Lanzon, JY Choe… - Kidney international, 2019 - Elsevier
Calcineurin inhibitors added to standard-of-care induction therapy for lupus nephritis (LN)
may increase complete renal remission (CRR) rates. The AURA-LV study tested the novel …
may increase complete renal remission (CRR) rates. The AURA-LV study tested the novel …
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry
…, YM Kang, CH Suh, WT Chung, YB Park, JY Choe… - Nature …, 2016 - nature.com
Systemic lupus erythematosus (SLE) has a strong but incompletely understood genetic
architecture. We conducted an association study with replication in 4,478 SLE cases and 12,656 …
architecture. We conducted an association study with replication in 4,478 SLE cases and 12,656 …
Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling
JY Choe, B Crain, SR Wu, M Corr - The Journal of experimental …, 2003 - rupress.org
Inflammatory arthritis is associated with the release of a network of key cytokines. In T cell
receptor transgenic K/BxN mice interleukin (IL)-1 plays a key role in joint swelling and …
receptor transgenic K/BxN mice interleukin (IL)-1 plays a key role in joint swelling and …
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe …
JY Choe, N Prodanovic, J Niebrzydowski… - Annals of the …, 2017 - ard.bmj.com
Objectives To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of
SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid …
SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid …
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
Objective Systemic lupus erythematosus (SLE), an autoimmune disorder, has been associated
with nearly 100 susceptibility loci. Nevertheless, these loci only partially explain SLE …
with nearly 100 susceptibility loci. Nevertheless, these loci only partially explain SLE …
[HTML][HTML] The prevalence of metabolic syndrome in patients with gout: a multicenter study
…, SH Baik, S Chung, CG Kim, JY Choe… - Journal of Korean …, 2005 - ncbi.nlm.nih.gov
It has been suggested that hyperuricemia and possibly gout are associated with the metabolic
syndrome, but there have been no direct studies. This study was undertaken to obtain the …
syndrome, but there have been no direct studies. This study was undertaken to obtain the …
The prevalence of diffuse idiopathic skeletal hyperostosis in Korea.
…, BR Choi, CG Kim, SH Chung, JY Choe… - The Journal of …, 2004 - jrheum.org
OBJECTIVE: To identify the prevalence of diffuse idiopathic skeletal hyperostosis (DISH) in
a large Asian population group. METHODS: A total of 3595 subjects (1616 men and 1979 …
a large Asian population group. METHODS: A total of 3595 subjects (1616 men and 1979 …
High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci
…, SS Lee, J Lee, WT Chung, JY Choe… - Annals of the …, 2015 - ard.bmj.com
Objective A highly polygenic aetiology and high degree of allele-sharing between ancestries
have been well elucidated in genetic studies of rheumatoid arthritis. Recently, the high-…
have been well elucidated in genetic studies of rheumatoid arthritis. Recently, the high-…
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with …
JS Smolen, JY Choe, N Prodanovic… - Annals of the …, 2018 - ard.bmj.com
Objectives Efficacy, safety and immunogenicity results from the phase III study of SB2, a
biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This …
biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This …